活化白细胞黏附分子在乳腺癌中的研究进展

doi:10.11904/j.issn.1002-3070.2024.01.007

实用肿瘤学杂志 ›› 2024, Vol. 38 ›› Issue (1): 45-49.doi: 10.11904/j.issn.1002-3070.2024.01.007

活化白细胞黏附分子在乳腺癌中的研究进展

谢俊岭

华北理工大学公共卫生学院(唐山 063210)

收稿日期:2022-12-26 修回日期:2023-03-08 出版日期:2024-02-28 发布日期:2024-06-21
通讯作者: 谢俊岭,E-mail:junlingxie@163.com
作者简介:谢俊岭,女,(1986-),博士研究生,从事肿瘤干细胞与肿瘤微环境相关的研究。
基金资助:
河北省自然科学基金资助项目(编号:H2020209037)

Research progress of activated leukocyte adhesion molecule in breast cancer

XIE Junling

School of Public Health,North China University of Science and Technology,Tangshan 063210,China

Received:2022-12-26 Revised:2023-03-08 Online:2024-02-28 Published:2024-06-21

摘要/Abstract

摘要： 乳腺癌是全球女性最常见的肿瘤,也是导致女性死亡最主要的疾病之一。肿瘤相关标志物及治疗靶点的研究已成为肿瘤领域的一个热点话题。研究发现活化白细胞黏附分子(Activated leukocyte cell adhesion molecule,ALCAM)在乳腺癌的发生发展过程中发挥重要的作用,并且与乳腺癌患者的预后具有相关性。本文针对ALCAM的分子结构特征、ALCAM与乳腺癌临床指征及预后的相关性,以及ALCAM作为乳腺癌临床诊断及治疗靶点的研究和应用进展进行综述。

关键词: 活化白细胞黏附分子, 乳腺癌, 肿瘤标志物

Abstract: Breast cancer is the most common cancer among women worldwide,and it is also one of the most important diseases that cause women′s death.The study of tumor related biomarkers and therapeutic targets has become a hot topic in the field of cancer.Studies have found that activated leukocyte cell adhesion molecule(ALCAM)plays an important role in the occurrence and development of breast cancer,and it is related to the prognosis of breast cancer patients.This article reviews the molecular characteristics of ALCAM,the correlation between ALCAM expression and breast cancer clinical feature and prognosis,and the research and application of ALCAM as a target for clinical diagnosis and treatment of breast cancer.

Key words: Activated leukocyte cell adhesion molecules, Breast cancer, Tumor biomarkers

中图分类号:

R737.9

谢俊岭. 活化白细胞黏附分子在乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2024, 38(1): 45-49.

XIE Junling. Research progress of activated leukocyte adhesion molecule in breast cancer[J]. Journal of Practical Oncology, 2024, 38(1): 45-49.

参考文献

1 Yang YM,Ye L,Ruge F,et al.Activated leukocyte cell adhesion Molecule(ALCAM),a potential′Seed′and′Soil′receptor in the peritoneal metastasis of gastrointestinal cancers[J].Int J Mol Sci,2023,24(1):876-897.
2 von Lersner A,Droesen L,Zijlstra A.Modulation of cell adhesion and migration through regulation of the immunoglobulin superfamily member ALCAM/CD166[J].Clin Exp Metastasis,2019,36(2):87-95.
3 Münsterberg J,Loreth D,Brylka,et al.ALCAM contributes to brain metastasis formation in non-small-cell lung cancer through interaction with the vascular endothelium[J].Neuro Oncol,2020,22(7):955-966.
4 Chalmers SA,Ayilam Ramachandran R,Garcia SJ,et al.The CD6/ALCAM pathway promotes lupus nephritis via T cell-mediated responses[J].J Clin Invest,2022,132(1):e147334.
5 Cho WJ,Mittal SK,Chauhan SK.Mesenchymal stromal cellssuppress T-cell-mediated delayed-type hypersensitivity via ALCAM-CD6 interaction[J].Stem Cells Transl Med,2023,12(4):221-233.
6 Yang Y,Sanders AJ,Dou QP,et al.The Clinical and theranostic values of activated leukocyte cell adhesion molecule(ALCAM)/CD166 in human solid cancers[J].Cancers(Basel),2021,13(20):5187-5214.
7 Darvishi B,Boroumandieh S,Majidzadeh-AK,et al.The role of activated leukocyte cell adhesion molecule(ALCAM)in cancer progression,invasion,metastasis and recurrence:A novel cancer stem cell marker and tumor-specific prognostic marker.Exp Mol Pathol[J].2020,115:104443-104451.
8 Ferragut F,Vachetta VS,Troncoso MF,et al.ALCAM/CD166:A pleiotropic mediator of cell adhesion,stemness and cancer progression[J].Cytokine Growth Factor Rev,2021,61:27-37.
9 Bartolomé RA,Pintado-Berninches L,Jaén M,et al.SOSTDC1 promotes invasion and liver metastasis in colorectal cancer via interaction with ALCAM/CD166[J].Oncogene,2020,39(38):6085-6098.
10 Chen X,Liang R,Lin H,et al.CD166 promotes cancer stem cell-like phenotype via the EGFR/ERK1/2 pathway in the nasopharyngeal carcinoma cell line CNE-2R[J].Life Sci,2021,267:118983-118990.
11 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries[J].CA Cancer J Clin,2021,71(3):209-249.
12 李福程,贾斯媛,巴玉玲,等.免疫检查点抑制剂在早期乳腺癌新辅助治疗中的研究进展[J].实用肿瘤学杂志,2023,37(4):367-371.
13 Hebron KE,Li EY,Arnold Egloff SA,et al.Alternative splicing of ALCAM enables tunable regulation of cell-cell adhesion through differential proteolysis[J].Sci Rep,2018,8(1):3208-3222.
14 Iwagishi R,Tanaka R,Seto M,et al.Negatively charged amino acids in the stalk region of membrane proteins reduce ectodomain shedding[J].J Biol Chem,2020,295(35):12343-12352.
15 King JA,Ofori-Acquah SF,Stevens T,et al.Activated leukocyte cell adhesion molecule in breast cancer:prognostic indicator[J].Breast Cancer Res,2004,6(5):478-487.
16 Davies SR,Dent C,Watkins G,et al.Expression of the cell to cell adhesion molecule,ALCAM,in breast cancer patients and the potential link with skeletal metastasis[J].Oncol Rep,2008,19(2):555-561.
17 Ihnen M,Müller V,Wirtz RM,et al.Predictive impact of activated leukocyte cell adhesion molecule(ALCAM/CD166)in breast cancer[J].Breast Cancer Res Treat,2008,112(3):419-427.
18 Ihnen M,Wirtz RM,Kalogeras KT,et al.Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2-and ER-negative breast cancer[J].Br J Cancer,2010,28;103(7):1048-1056.
19 Bartolomé RA,Pintado-Berninches L,Jaén M,et al.SOSTDC1 promotes invasion and liver metastasis in colorectal cancer via interaction with ALCAM/CD166[J].Oncogene,2020,39(38):6085-6098.
20 Yang Y,Ma Y,Gao H,et al.A novel HDGF-ALCAM axis promotes the metastasis of Ewing sarcoma via regulating the GTPases signaling pathway[J].Oncogene,2021,40(4):731-745.
21 Burkhardt M,Mayordomo E,Winzer KJ,et al.Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer[J].J Clin Pathol,2006,59(4):403-409.
22 Burandt E,Bari Noubar T,Lebeau A,et al.Loss of ALCAM expression is linked to adverse phenotype and poor prognosis in breast cancer:a TMA-based immunohistochemical study on 2,197 breast cancer patients[J].Oncol Rep,2014,32(6):2628-2634.
23 Tan F,Mosunjac M,Adams AL,et al.Enhanced down-regulation of ALCAM/CD166 in African-American Breast Cancer[J].BMC Cancer,2014,25;14:715-722.
24 Piao D,Jiang T,Liu G,et al.Clinical implications of activated leukocyte cell adhesion molecule expression in breast cancer[J].Mol Biol Rep,2012,39(1):661-668.
25 Renard HF,Tyckaert F,Lo Giudice C,et al.Endophilin-A3 and Galectin-8 control the clathrin-independent endocytosis of CD166[J].Nat Commun,2020,11(1):1457-1469.
26 Kulasingam V,Zheng Y,Soosaipillai A,et al.Activated leukocyte cell adhesion molecule:a novel biomarker for breast cancer[J].Int J Cancer,2009,25(1):9-14.
27 Al-Shehri FS,Abd El Azeem EM.Activated leukocyte cell adhesion molecule(ALCAM)in saudi breast cancer patients as prognostic and predictive indicator[J].Breast Cancer(Auckl),2015,23(9):81-86.
28 Zarghami N,Soto MS,Perez-Balderas F,et al.A novel molecular magnetic resonance imaging agent targeting activated leukocyte cell adhesion molecule as demonstrated in mouse brain metastasis models[J].J Cereb Blood Flow Metab,2021,41(7):1592-1607.
29 Darvishi B,Salehi M,Boroumandieh S,et al.Dual in vitro invasion/migration suppressing and tamoxifen response modulating effects of a recombinant anti-ALCAM scFv on breast cancer cells[J].Cell Biochem Funct,2020,38(5):651-659.
30 Boni V,Fidler MJ,Arkenau HT,et al.Praluzatamab ravtansine,a CD166-targeting antibody-drug conjugate,in patients with advanced solid tumors:An open-label phase Ⅰ/Ⅱ Trial[J].Clin Cancer Res,2022,28(10):2020-2029.

[1]	郑鹏飞, 董良鹏, 高延鑫, 张一夫, 秦双. 白细胞介素-38对乳腺癌患者CD8⁺T淋巴细胞功能的影响[J]. 实用肿瘤学杂志, 2024, 38(1): 30-36.
[2]	冯楚然, 曹剑钊, 陈子印, 张大昕, 鲁海玲. 乳腺癌放射性心脏损伤及其预防措施的研究进展[J]. 实用肿瘤学杂志, 2023, 37(6): 513-518.
[3]	赵诗璐, 庞达. 乳腺癌预后相关基因的生物信息学筛选与分析[J]. 实用肿瘤学杂志, 2023, 37(5): 422-428.
[4]	初思彤, 许庆勇. 三阴性乳腺癌免疫治疗耐药机制的研究进展[J]. 实用肿瘤学杂志, 2023, 37(5): 449-453.
[5]	王新萍, 张自云, 王学东. 非编码RNA在乳腺癌化疗耐药中作用的研究进展[J]. 实用肿瘤学杂志, 2023, 37(5): 454-458.
[6]	鲁泓男, 夏冰舒, 乔坤, 张世园, 黄元夕, 鲁祥石. GAS1与乳腺癌免疫治疗及药物敏感性的关系[J]. 实用肿瘤学杂志, 2023, 37(4): 351-359.
[7]	陈飞, 王颖, 曾传琴. B7-H4在乳腺癌组织中的表达及其与患者新辅助化疗后腋窝淋巴结转移的相关性分析[J]. 实用肿瘤学杂志, 2023, 37(4): 360-366.
[8]	李福程, 贾斯媛, 巴玉玲, 罗丹利, 肖敏. 免疫检查点抑制剂在早期乳腺癌新辅助治疗中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(4): 367-371.
[9]	马艳玲, 钱立庭, 魏东华, 尹惠萍, 张娟, 张小鹏. 2014—2017年安徽省合肥市城市乳腺癌高危人群筛查率及其影响因素分析[J]. 实用肿瘤学杂志, 2023, 37(3): 200-206.
[10]	隋世尧, 郑玮, 杨子涵, 庞达. lncRNA SNHG4通过EP300-SNHG4-GPX4轴抑制乳腺癌细胞铁死亡[J]. 实用肿瘤学杂志, 2023, 37(3): 215-223.
[11]	张庆怀, 韩阿蒙, 杨森, 李秀梅, 赵健鑫, 张彦秋. 乳腺癌患者保乳术后五种放疗技术的疗效比较研究[J]. 实用肿瘤学杂志, 2023, 37(3): 224-229.
[12]	杨帅, 王新恒, 吴佳乐, 付子彤, 魏博, 杨灵冰, 许守平. 单细胞测序技术在乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(3): 287-292.
[13]	张馨, 吴羡美, 李虹, 刘晓舟, 孔德文, 陈琢. 1990—2019年中国女性人群归因于代谢危险因素的乳腺癌疾病负担[J]. 实用肿瘤学杂志, 2023, 37(2): 107-111.
[14]	刘欣欣, 马西元, 缪美琪, 王语晴, 陈晶. IL-6及其受体在乳腺癌治疗中的作用研究进展[J]. 实用肿瘤学杂志, 2023, 37(2): 149-154.
[15]	冯诚天, 黄芙蓉, 姜永冬. 脂质代谢与乳腺癌曲妥珠单抗耐药性机制的相关性研究[J]. 实用肿瘤学杂志, 2023, 37(2): 155-159.

活化白细胞黏附分子在乳腺癌中的研究进展

Research progress of activated leukocyte adhesion molecule in breast cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价